Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab.
Ran RanWenfa HuangYaxin LiuLin ShaoXiaoran LiuYunyun NiuWeiyao KongShiping BoHope S RugoSijia LuHuiping LiPublished in: OncoTargets and therapy (2020)
In this population of patients with HER2-positive MBC, individuals with high HER2 GCNs in plasma had worse prognosis after trastuzumab-based therapy. Plasma HER2 GCN may be a prognostic marker in these patients.